Findings in a single-center study show women with breast cancer who undergo nipple-sparing mastectomy have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
